参考文献/References:
[1] Thom T, Haase N, Rosamond W,et al. Heart disease and stroke statistics——2006 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee[J]. Circulation,2006,113(6): e85-e151.
[2] Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study:a population based study[J].Lancet, 2001,358(9280):439-444.
[3] Hobbs FD, Roalfe AK, Davis RC, et al. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction:5 year mortality follow-up of the Echocardiographic Heart of England Screening Study(ECHOES)[J]. Eur Heart J,2007,28(9):1128-1134.
[4] Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction[J]. N Engl J Med, 2011,364(17):1607-1616.
[5] Biondi-Zoccai G, Sheiban I, Moretti C, et al. Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease:insights from a multicenter registry of 975 patients[J]. Clin Res Cardiol,2011,100:403-411.
[6] Daneault B, Généreux P, Kirtane AJ,et al. Comparison of three-year outcomes after primary percutaneous coronary intervention in patients with left ventricular ejection fraction<40% versus ≥40%(from the HORIZONS-AMI trial)[J]. Am J Cardiol,2013,111(1):12-20.
[7] Alidoosti M, Salarifar M, Zeinali AM,et al.Short- and long-term outcomes of percutaneous coronary intervention in patients with low, intermediate and high ejection fraction[J]. Cardiovasc J Afr,2008,19:17-21.
[8] Bouchart F, Tabley A, Litzler PY,et al. Myocardial revascularization in patients with severe ischemic left ventricular dysfunction. Long-term follow-up in 141 patients[J]. Eur J Cardiothorac Surg,2001,20(6):1157-1162.
[9] di Sciascio G, Patti G, D'Ambrosio A,et al. Coronary stenting in patients with depressed left ventricular function:acute and long-term results in a selected population[J]. Cathter Cardiovasc Interv,2003,59(4):429-433.
[10] Li C, Jia G, Guo W,et al. Stent supported coronary angioplasty in patients with severe ventricular dysfunction[J]. Chin Med J(Engl), 2002,115(3):355-358.
[11] Prapas SN, Tsakiridis K, Zarogoulidis P, et al. Current options for treatment of chronic coronary artery disease[J]. J Thorac Dis,2014,6(Suppl 1):S2-S6.
[12] Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction[J]. N Engl J Med,2011,364:1617-1625.
[13] di Carli MF. Myocardial Viability Assessment with PET and PET/CT. In:Di Carli M.F, Lipton M.J. Cardiac PET and PET/CT imaging[M]. New York: Springer Verlag, 2007:250-267.
[14] Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis[J]. J Am Coll Cardiol, 2002,39(7):1151-1158.
[15] Appoo J, Norris C, Merali S, et al.Long-term outcome of isolated coronary artery bypass surgery in patients with severe left ventricular dysfunction[J]. Circulation,2004,110(11 Suppl 1):Ⅱ13-Ⅱ17.
[16] Chung S, Kim WS, Jeong DS,et al. Outcomes of off-pump coronary bypass grafting with the bilateral internal thoracic artery for left ventricular dysfunction[J]. J Korean Med Sci,2014,29(1):69-75.
[17] Kunadian V, Zaman A, Qiu W. Revascularization among patients with severe left ventricular dysfunction:a meta-analysis of observational studies[J]. Eur J Heart Fail,2011,13(7):773-784.
[18] Nusca A, Lipinski MJ, Varma A, et al. Safety of drug-eluting stents in patients with left ventricular dysfunction undergoing percutaneous coronary intervention[J].Am J Cardiol,2008,102(6):679-682.
[19] Briguori C, Aranzulla TC, Airoldi F, et al. Stent implantation in patients with severe left ventricular systolic dysfunction[J]. Int J Cardiol,2009, 135:376-384.
[20] Aslam F, Blankenship JC. Coronary artery stenting in patients with severe left ventricular dysfunction[J]. J Invasive Cardiol,2005,17:656-658.
[21] Bukachi F, Clague JR, Waldenstrom A,et al. Clinical outcome of coronary angioplasty in patients with ischaemic cardiomyopathy[J].Int J Cardiol,2003,88:167-174.
[22] Sheiban I, MorettiC, Biondi Zoccai G,et al. Short- and long-term outcomes of percutaneous coronary interventions in patients with severe left ventricular dysfunction[J]. EuroIntervention,2007,3:359-364.
[23] Li C, Jia G, Guo W, et al. Stent supported coronary angioplasty in patients with severe ventricular dysfunction[J]. Chin Med J(Engl),2002,115:355-358.
[24] Keelan PC, Johnston JM, Koru-Sengul T,et al. Comparison of in-hospital and one-year outcomes in patients with left ventricular ejection fractions <or = 40%, 41% to 49%, and >or = 50% having percutaneous coronary revascularization[J]. Am J Cardiol,2003,91:1168-1172.
[25] Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation[J]. N Engl J Med,2005,352:2174-2183.
[26] Morice MC, Serruys PW, Kappetein AP,et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery(SYNTAX)trial[J]. Circulation,2010,121:2645-2653.
[27] Mohr FW, MoriceM C, Kappetein AP, et al.Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease:5-year follow-up of the randomised, clinical SYNTAX trial[J]. Lancet,2013,381(9867):629-638.
[28] Detre KM, Lombardero MS, Brooks MM, et al. The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction[J]. N Engl J Med,2000,342(14):989-997.
[29] Wijns W, Kolh P, Danchin N, et al. Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS),European Association for Percutaneous Cardiovascular Interventions(EAPCI). Guidelines on myocardial revascularization[J]. Eur Heart J,2010,31(20): 2501-2555.
[30] Hillis LD, Smith PK, Anderson JL, et al.2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines:developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons[J]. J Am Coll Cardiol,2011,58(24):e123-e210.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(1):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[3]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(1):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[4]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(1):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[5]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(1):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[6]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(1):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[7]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(1):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[8]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(1):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[9]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
[10]方砚 王效浣 郭朝霞.血流介导性血管扩张评价心血管病患者肱动脉内皮功能的研究进展[J].心血管病学进展,2019,(5):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]
FANG Yan,WANG Xiaohuan,GUO Zhaoxia.Flow- mediated Vasodilation Evaluation of Brachial Artery Endothelial Function in Patients with Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]